Drugs in ATC Class N02AD

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N02 - ANALGESICS

Up to N02A - OPIOIDS

Drugs in ATC Class: N02AD - Benzomorphan derivatives

Tradename	Generic Name
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE	acetaminophen; pentazocine hydrochloride
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride
TALACEN	acetaminophen; pentazocine hydrochloride
TALWIN COMPOUND	aspirin; pentazocine hydrochloride

N02AD Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class N02AD (Benzomorphan derivatives) reflect a niche but evolving segment in pain management, driven by innovation and regional prescribing trends. Below is a detailed analysis:

---

Market Dynamics

1. Growth Drivers and Forecasts

• The Pentazocine HCl market (a key N02AD drug) is projected to grow at a 5.2% CAGR (2023–2031), driven by rising demand for opioid analgesics in pain management[10][13].
• Regional disparities exist:
  • Asia-Pacific shows growth due to expanding healthcare infrastructure and chronic pain prevalence[10].
  • In Croatia, opioid prescriptions (including N02AD) rose by 51% over 11 years, though Benzomorphans accounted for <1% of total analgesic prescriptions[3].
  • Norway reported negligible Benzomorphan use, with 0.00 DDD/TDS (defined daily doses per 1,000 inhabitants/day)[8].

2. Key Market Segments

• Formulations: Injections dominate due to rapid onset in acute pain[10][13].
• Distribution: Hospital pharmacies lead, but online channels are growing[10].
• Players: Lupin, Sun Pharma, Watson Labs, Sanofi, and Mylan hold significant shares[10].

3. Regulatory and Usage Trends

• Strict opioid regulations in Europe limit adoption (e.g., Norway)[8].
• Emerging markets prioritize cost-effective generics (e.g., pentazocine combinations like Talwin)[5][10].

---

Patent Landscape

1. Key Patents and Innovations

• Core Compounds:
  • Pentazocine combinations (e.g., with naloxone, acetaminophen) are patented for abuse deterrence[5].
  • Novel derivatives:
  • 6,7-Benzomorphans targeting NMDA receptors (e.g., Merck’s NMDA antagonists)[7][16].
  • N-substituted Benzomorphans with biased MOR agonism (e.g., LP1 derivatives reducing gastrointestinal side effects)[15].

2. Strategic Patenting Trends

• Drug-device combinations: Companies seek patents for synergistic delivery systems (e.g., implantable devices), requiring proof of non-obviousness[11].
• Structural modifications: Alkylation or hydroxyl-group shifts improve receptor specificity (e.g., compound 15cr.HCl with enhanced NMDA affinity)[16].

3. Expiry and Competition

• Older patents (e.g., basic pentazocine formulations) have expired, enabling generic competition[14].
• Recent patents focus on:
  • Extended-release formulations.
  • Prodrugs with lower addiction liability[15].

---

Challenges and Opportunities

Factor	Impact
Regulatory barriers	Strict controls on opioids limit market expansion in high-income regions[8][9].
Competition	Dominance of alternative opioids (e.g., fentanyl, tramadol) in acute pain[9].
Innovation potential	Biased agonists (e.g., LP1 derivatives) may reduce side effects, driving R&D[15].

---

Key Takeaways

• The N02AD market is regionally fragmented, with growth concentrated in emerging economies.
• Patent strategies prioritize abuse-deterrent combinations and receptor-specific derivatives.
• While older Benzomorphans face generic competition, novel analogues (e.g., NMDA-targeting compounds) could revitalize the segment[7][16].

Highlight: "Modifications at the basic nitrogen of the benzomorphan scaffold allowed the development of compounds able to segregate physiological responses downstream of receptor signaling." [15]

References

1. https://en.wikipedia.org/wiki/ATC_code_N02
2. https://patents.google.com/patent/EP0028717A1/en
3. https://hrcak.srce.hr/file/469614
4. https://www.globenewswire.com/news-release/2025/03/11/3040791/28124/en/Bromine-Derivatives-Market-Report-2025-Bromine-Derivatives-Market-to-Grow-at-7-4-CAGR-Amid-Rising-Demand-for-Flame-Retardants-Water-Treatment-Solutions.html
5. https://www.drugpatentwatch.com/p/atc-class/N02AD
6. https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=N02AD
7. https://patents.justia.com/patent/4332807
8. https://www.fhi.no/contentassets/00c2c40952bb4c3da07216b656b72a7b/rapport-legemiddelstatistikk-2020.pdf
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4584929/
10. https://www.theinsightpartners.com/reports/pentazocine-hcl-market
11. https://www.lexorbis.com/ways-to-patent-a-drug-device-combination/
12. https://patents.justia.com/inventor/herbert-merz
13. https://www.marketresearchintellect.com/product/global-pentazocine-api-market/
14. https://gabi-journal.net/patent-expiry-dates-for-biologicals-2018-update.html
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7236032/
16. https://pubmed.ncbi.nlm.nih.gov/9288174/